[1] Kulinich DP,Sheppard JP,Nguyen T,et al.Radiotherapy versus combination radiotherapy-bevacizumab for the treatment of recurrent high-grade glioma:a systematic review[J].Acta Neurochirurgica,2021,163(7):1921~1934. [2] ChagantiJ,Taylor M,Woodford H,et al.Differentiation of primary CNS lymphoma and high-grade glioma with dynamic susceptibility contrast derived metrics:A Pilot Study[J].World Neurosurgery,2021,151:e979~e987. [3] Xz A,Mz A,Na ZC,et al.Discovery of linear unnatural peptides as potent mutant isocitrate dehydrogenase 1 inhibitors by Ugi reaction[J].Bioorganic Chemistry,2021,119:105569. [4] Luna LA,Lesecq Z,White KA,et al.An acidic residue buried in the dimer interface of isocitrate dehydrogenase 1 (IDH1) helps regulate catalysis and pH sensitivity[J].Biochemical Journal,2020,477(16):2999~3018. [5] Sesanto R,Kuehn JF,Barber DL,et al.Low pH Facilitates heterodimerization of mutant Isocitrate dehydrogenase IDH1-R132H and promotes production of 2-Hydroxyglutarate[J].Biochemistry,2021,60(25):1983~1994. [6] Haeng KS,Jihwan Y,Dongkyu L,et al.Influence of the amount of fresh specimen on the Isolation of tumor mesenchymal stem-like cells from high-grade glioma[J].Yonsei medical journal,2021,62(10):936~942. [7] KlingenschmidJ,Krigers A,Pinggera D,et al.The clinical frailty scale as predictor of overall survival after resection of high-grade glioma[J].Journal of Neuro-Oncology,2022,158(1):15~22. [8] KalidindiN,Or R,Babak S,et al.Molecular classification of diffuse gliomas[J].Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques,2020,47(4):464~473. [9] Anderson SE,Fahey NS,Park J,et al.A high-throughput SAMDI-Mass spectrometry assay for isocitrate dehydrogenase 1[J].The Analyst,2020,145(11):3899~3908. [10] 王大堃,朱建忠,刘辉,等.DCE-MRI测量Ktrans值、Ve值联合ADC值与脑胶质瘤患者MVD及病理分期的相关性[J].中国临床医学影像杂志,2020,31(11):766~769. [11] 周之怀,王健.MRI增强扫描及表观扩散系数值在脑转移瘤和高级别胶质瘤鉴别诊断的价值分析[J].临床放射学杂志,2020(3):446~451. [12] 朱巍,高燕,王培军.多模态功能MRI评估脑胶质瘤IDH1突变状态的研究[J].中国医学计算机成像杂志,2021,27(3):179~184. [13] 冷冰,任岩,陈海清.磁共振ASL与DTI在脑神经胶质瘤诊断中的应用价值分析[J].中国CT和MRI杂志,2022,20(4):1816~1835. [14] 沈烨,谢红,恽健,等.探讨磁共振SWI序列对脑胶质瘤术前分级的应用价值[J].中国CT和MRI杂志,2020,18(8):13~15,59. [15] 卢海涛,邢伟,张艳文,等.动态对比增强MRI纹理分析预测高级别胶质瘤IDH基因表型的价值[J].中华放射学杂志,2020,54(5):450~455. [16] 朱巍,高燕,王培军.多模态功能MRI评估脑胶质瘤IDH1突变状态的研究[J].中国医学计算机成像杂志,2021,27(3):179~184. [17] 邢士军,王莉,张丽君.IVIM-MRI对人脑胶质瘤的病理分级及IDH1基因突变的评估价值[J].中国临床神经外科杂志,2020,25(12):821~824. [18] 汪洁,包善磊,贾中正,等.动态对比增强磁共振成像纹理分析评估胶质瘤IDH1突变与瘤细胞增殖[J].中国医学影像学杂志,2021,29(7):659~664. [19] 朱文标,卢善明,李海南,等.联合IDH1、1p/19q和ATRX对胶质瘤分子分型的临床意义[J].南昌大学学报:医学版,2020(4):41~45. |